Pluri Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Pluri Inc. (PLUR) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period of 1.01 million shares for the 6-month period ending 2023-12-31, per its 10-Q filed 2024-02-12.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod · last filed 2024-02-12
- Pluri Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2023-12-31 was 3.29K shares, a 70.57% decline year-over-year.
- Pluri Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2023-09-30 was 1.00M shares, a 3491.55% increase year-over-year.
- Pluri Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2023-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- Pluri Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2023-03-31 was 12.25K shares.
- Pluri Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2023 was 51.39K shares, a 3.42% increase from fiscal 2022.
- Pluri Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2022 was 49.69K shares, a 70.98% increase from fiscal 2021.
- Pluri Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2021 was 29.06K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 12 month |
|---|---|---|---|---|
| 2023-12-31 | 3.29K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-12 | 1.01M shares 10-Q · filed 2024-02-12 | 1.01M shares derived: sum of 3 quarters · filed 2024-02-12 | 1.02M shares derived: sum of 4 quarters · filed 2024-02-12 |
| 2023-09-30 | 1.00M shares 10-Q · filed 2023-11-13 | 1.00M shares derived: sum of 2 quarters · filed 2023-11-13 | 1.02M shares derived: sum of 3 quarters · filed 2023-11-13 | 1.03M shares derived: sum of 4 quarters · filed 2024-02-12 |
| 2023-06-30 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-12 | 12.25K shares derived: sum of 2 quarters · filed 2023-09-12 | 23.44K shares derived: sum of 3 quarters · filed 2024-02-12 | 51.39K shares 10-K · filed 2023-09-12 |
| 2023-03-31 | 12.25K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-09 | 23.44K shares derived: sum of 2 quarters · filed 2024-02-12 | 51.39K shares 10-Q · filed 2023-05-09 | 60.05K shares derived: sum of 4 quarters · filed 2024-02-12 |
| 2022-12-31 | 11.19K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-12 | 39.14K shares 10-Q · filed 2024-02-12 | 47.80K shares derived: sum of 3 quarters · filed 2024-02-12 | |
| 2022-09-30 | 27.95K shares 10-Q · filed 2023-11-13 | 36.61K shares derived: sum of 2 quarters · filed 2023-11-13 | ||
| 2022-06-30 | 8.66K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-12 | 49.69K shares 10-K · filed 2023-09-12 | ||
| 2022-03-31 | 41.03K shares 10-Q · filed 2023-05-09 | |||
| 2021-06-30 | 29.06K shares 10-K · filed 2022-09-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B |